Fig. 4From: Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN® datasetTime to discontinuation for aquaretic events, hepatic events, and other discontinuationsBack to article page